Some individuals will simply be beginning out on their investing journeys in April. Whereas thrilling, it will also be daunting taking a look at all of the choices. The place on earth to start out? Right here, I’ll spotlight a trio of high-quality FTSE 100 shares that I feel are value contemplating for a brand new ISA portfolio.

Pharmaceutical big

Large Pharma typically will get a nasty rep these days, however the place would tens of millions of sufferers be with out the life-saving medicines? AstraZeneca (LSE: AZN) is the UK’s largest listed firm and a world chief in oncology (most cancers remedies).

Final yr, complete income jumped 21% at fixed change charges to $54.1bn, whereas core earnings per share (EPS) elevated 19%. By 2030, it’s aiming to launch no less than 20 new medicines and attain $80bn in income, with sustained development thereafter. 

At £111 a pop, the shares are buying and selling at 16.5 occasions forward-looking earnings. I feel this can be a affordable valuation for a high-quality world firm, although it may all the time undergo a key scientific trial or regulatory setback. These are unavoidable dangers within the trade.

Nonetheless, AstraZeneca’s fundamentals are rock-solid. It’s very worthwhile, excellently run, and has engaging long-term development alternatives. The shares additionally presents a dividend, with the ahead yield at 2.3%.

All this makes it a wonderful candidate for a brand new ISA, in my view.

Main credit score bureau

From a pharma big to an information one now with Experian (LSE: EXPN). The credit score reporting firm possesses an enormous assortment of knowledge on shoppers and companies, primarily associated to credit score and monetary behaviour. Its instruments additionally assist detect and stop identification fraud.

For the six months to 30 September, income was up 7% to $3.6bn, with EPS rising 9%. For the total yr that simply resulted in March, Experian expects natural income development of 6%-8%.

Whereas these may not appear thrilling development charges, it’s necessary to keep in mind that many lenders, insurers and entrepreneurs depend on Experian. This implies a big chunk of its income is recurring, making it very secure and predictable.

Importantly, its high-quality datasets are a goldmine for coaching AI fashions, one thing it has been doing for twenty years. Generative AI is merely strengthening its enterprise additional.

Experian has simply acquired ClearSale, a number one digital fraud prevention supplier in Brazil. This provides e-commerce transactions, cell phone and system information to the combination, strengthening its merchandise and aggressive place in Latin America’s largest economic system. 

The potential of a shopper information breach is a danger, as this is able to trigger vital reputational injury. In the meantime, the inventory isn’t low-cost, buying and selling at 25.5 occasions ahead earnings. It’s priced for regular long-term development, which should proceed.

I’m bullish on the inventory although. Digital lending within the type of purchase now, pay later is exploding worldwide, which ought to proceed benefiting Experian. 

Know-how fund

Lastly, I feel Polar Capital Know-how Belief is value contemplating Too. This funding belief presents huge publicity to many world tech titans, together with Nvidia, Broadcom, Apple, and Meta Platforms.

The share price has nearly doubled in 5 years. Nonetheless, it hasn’t all the time been a clean experience and extra bumps within the street are assured. Proper now, for instance, President Trump’s tariff insurance policies may trigger earnings volatility at world tech firms.

Nonetheless, long term, I count on this belief to extend in worth as the continued digital/AI revolution gathers steam.